VEGFA and hepatocellular carcinoma: The first agents approved for the treatment of advanced HCC were the tyrosine kinase inhibitors Sorafenib, Lenvatinib, Regorafenib, and Cabozantinib, which are oral agents that act primarily on VEGF receptors to mimic VEGF ligands, leading to the downregulation of several proliferative pathways; in particular, they counteract neoangiogenesis.